Monday, February 4, 2008

Taligen Raises $65M in Series B Funding

Biotechnology firm Taligen Therapeutics announced last week that it has concluded its second round of venture financing after securing $65 million. The company credited Alta Partners and Clarus Ventures with leading the effort. Existing investors Sanderling Ventures, Tango and High Country Venture also participated, Taligen said. Timothy Mills, Taligen's chairman of the board, noted that, as a result of the funding, Alta's Edward Hurwitz and Clarus' Nicholas Galakatos have joined the Aurora, Colo.-based company’s board of directors. Taligen manufactures monoclonal antibodies and recombinant fusion proteins that are used as anti-inflammatory agents. Both products are in pre-clinical stages of development. More information »